Faculty & Staff

Andrew P. Fontenot, MD - Henry N. Claman Associate Professor of Medicine

Division of Allergy & Clinical Immunology
Division Head, Allergy and Clinical Immunology
4200 East Ninth Ave, B164
Denver, CO 80262
Phone: (303) 315 1133
Fax: (303) 315 7642
Andrew.Fontenot@uchsc.edu

Education:
1982-1986 BS (Zoology) Louisiana State University, Baton Rouge, Louisiana
1986-1990 MD Louisiana State University School of Medicine, New Orleans, Louisiana
1990-1993 Internship and Residency (Internal Medicine), University of Alabama-Birmingham, Birmingham, Alabama
1993-1994 Chief Medical Resident, University of Alabama-Birmingham, Birmingham, Alabama
1994-1998 Fellowship (Pulmonary/Critical Care), University of Colorado, Denver, Colorado
Board Certification:
Diplomate, American Board of Internal Medicine, 1994, Recertified 2004
Diplomate, American Board of Internal Medicine, Pulmonary Diseases, 1996, Recertified 2004
Diplomat, American Board of Internal Medicine, Critical Care Medicine, 1997
Colorado State Medical License
Areas of Clinical Interest:
Interstitial Lung Disease
Granulomatous Lung Disease
Clinic Location:
University of Colorado Hospital Pulmonary Clinic
4200 East 9th Avenue and Colorado Blvd.
First floor, West Wing, Room 1124
Clinic Days:
Tuesday Afternoon
Appointment Contact:
303-372-8156
Research Interests:
The interests of the laboratory are diverse, but mainly center on the role of T cells in the development of lung disease. In particular, the laboratory is interested in determining the mechanism by which CD4+ T cells recognize the beryllium antigen in the context of HLA-DP2. The immunologic mechanisms involved in the progression from beryllium sensitization and disease as well as the development of biomarkers that could potentially detect this progression in the absence of invasive procedures is also a major interest.
Research Team:
Michael Falta
Doug Mack
Allison Martin
Recent Publications:
Sawyer RT, Parsons CE, Fontenot AP, Maier LA, Gillespie M, Gottschall B, Silveira L, and Newman LS. HLA-DP mediates beryllium stimulated TNF-α production in chronic beryllium disease. Am. J. Respir. Cell Mol. Biol. 2004; 31:122-130.
Sawyer RT, Day BJ, Fadok VA, Chiarappa-Zucca M, Maier LA, Fontenot AP, Silviera L, and Newman LS. Beryllium-ferritin: lymphocyte proliferation and apoptosis in chronic beryllium disease. Am. J. Respir. Cell Mol. Biol. 2004; 31:470-477.
Sawyer RT, Dobis DR, Goldstein M, Velsor L, Maier LA, Fontenot AP, Silveira L, Newman LS, Day BJ. Beryllium-stimulated reactive oxygen species and macrophage apoptosis. Free Radic Biol Med. 2005; 38:928-937.
Chou YK, Edwards DM, Weinberg AD, Vandenbark AA, Kotzin BL, Fontenot AP, and Burrows GG. Activation pathways implicate anti-HLA-DP and anti-LFA-1 antibodies as lead candidates for intervention in chronic berylliosis. J. Immunol. 2005; 174:4316-4324.
Taraseviciene-Stewart L, Scerbavicius R, Choe K-H, Moore M, Sullivan AK, Nichols M, Fontenot AP, Tuder RM, Voelkel NF. An animal model of autoimmune emphysema. Am. J. Respir. Crit. Care Med. 2005; 171:734-742.
Pott GB, Palmer BE, Sullivan AK, Silviera L, Maier LA, Newman LS, Kotzin BL, and Fontenot AP. Frequency of beryllium-specific, Th1-type cytokine-expressing CD4+ T cells in patients with beryllium-induced disease. J. Allergy Clin. Immunol. 2005; 115:1036-1042.
Falta MT, Fontenot AP, Rosloniec EF, Crawford F, Roark CL, Bill J, Marrack P, Kappler J, and Kotzin BL. MHC Class II/peptide tetramer staining in relation to functional avidity and TCR diversity in the mouse CD4+ T cell response to a rheumatoid arthritis associated antigen. Arthritis Rheum. 2005; 52:1885-1896.
Sullivan AK, Simonian P, Falta MT, Cosgrove GP, Brown KK, Kotzin BL, Voelkel NF, Fontenot AP. Oligoclonal CD4+ T cells in the lungs of patients with severe emphysema. Am. J. Respir. Crit. Care Med. 2005; 172:590-596.
Fontenot AP, Palmer BE, Sullivan AK, Joslin FG, Wilson CC, Maier LA, Newman LS, Kotzin BL. Frequency of beryllium-specific, central memory CD4+ T cells in blood determines proliferative response. J. Clin. Invest. 2005; 115:2886-2893.
Fontenot AP and Maier LA. Genetic susceptibility and immune-mediated destruction in beryllium-induced disease. Trends Immunol. 2005; 26:543-549.
Bill JR, Mack DG, Falta MT. Maier LA. Joslin FG, Martin AK, Freed BM, Kotzin BL, Fontenot AP. Beryllium presentation to CD4+ T cells is dependent on a single amino acid residue of the MHC class II Β-chain. J. Immunol. 2005; 175:7029-7037.
Palmer BE, Blyveis N, Fontenot AP, and Wilson CC. Functional and phenotypic characterization of CD57+ T cells and their association with HIV-1-induced T cell dysfunction. J. Immunol. 2005; 175:8415-8423.
Fontenot AP, Edwards DM, Chou YK, Mack DG, La Tocha D, Vandenbark AA, and Burrows GG. Self-presentation of beryllium by BAL CD4+ T cells: T cell-T cell interactions and their role in chronic beryllium disease. Eur. J. Immunol. 2006; 36:930-939.
Lynes MA, Fontenot AP, Lawrence DA, Rosenspire AJ and Pollard KM. Gene expression influences on metal immunomodulation. Toxicol. Appl. Pharm. 2006; 210:9-16.
Amicosante M and Fontenot AP. T cell recognition in chronic beryllium disease. Clin. Immunol. 2006; 121:134-143.
Fontenot AP, Keizer TS, McCleskey M, Mack DG, Meza-Romero R, Chou YK, Vandenbark AA, Scott B, and Burrows GG. Recombinant HLA-DP2 binds beryllium and tolerizes beryllium-specific pathogenic T cells. J. Immunol. 2006; 177:3874-3883.
Sullivan AK, Simonian P, Falta MT, Cosgrove GP, Brown KK, Kotzin BL, Voelkel NF, Fontenot AP. Activated oligoclonal CD4+ T cells in the lungs of patients with severe emphysema. Proc. Am. Thor. Soc. 2006; 3:486.
Simonian PL, Roark CL, Diaz del Valle F, Palmer BE, Douglas I, Ikuta K, Born WK, O’Brien RL, and. Fontenot AP. Role of Υδ T cells in the recruitment of CD4+ and CD8+ T cells to lung and subsequent pulmonary fibrosis. J. Immunol. 2006; 177:4436-4443.
Mack CL, Tucker RM, Lu BR, Sokol RJ, Fontenot AP, Ueno Y, and Gill RG. Cellular and humoral autoimmunity directed at bile duct epithelia in murine biliary atresia. Hepatology 2006; 44:1231-1239.
Sawyer RT, Fontenot AP, Barnes TA, Parsons CE, Tooker BC, Maier LA, Gillespie MM, Gottschall EB, Silveira L, Hagman J, and Newman LS. Beryllium-induced TNF-Α production is transcriptionally-dependent in chronic beryllium disease. Am. J. Respir. Cell Mol. Biol. 2007; 36:191-200.
Palmer BE, Mack DG, Martin AK, Maier LA, and Fontenot AP. CD57 expression correlates with alveolitis severity in subjects with beryllium-induced disease. J. Allergy Clin. Immunol. In press.
Recent Book Chapters:
Sawyer, R.T., Maier, L.A., Fontenot, A.P., and Newman L.S. Chronic Beryllium Disease. In: Occupational Allergology. (Palczynski C, Kiec-Swierczynska M, eds) 1st Edition. Nofer Institute of Occupational Medicine. In press.
Fontenot AP, Kotzin BL. Immune Recognition and Responses. In: Textbook of Respiratory Medicine. (Mason RJ, Broaddus VC, Murray JF, Nadel JA, eds) 4th Edition, W.B. Saunders Company. 2004: 377-405.
Fontenot AP, Schwarz MI. Immunologic Lung Disease. In: Clinical Immunology: Practices and Principles. (Rich RR, Shearer WT, Fleisher TA, Schroeder HW, Weyand CM, Frew AJ, eds) 3rd Edition, Elsevier. In press.

Site Last Updated: 5/3/2007